GIGAIPC Unveils Jetson Orin Series at COMPUTEX 2025, Advancing Industrial-Grade AI Solutions
Hisense Shines at Cannes as Named Partner of CHINA NIGHT
Hisense Shines at Cannes as Named Partner of CHINA NIGHT
SNS812, an innovative siRNA drug from Oneness and Microbio (Shanghai), selected for ATS 2025 oral presentation, demonstrating world-leading clinical o
Huawei Cloud Credence Forum Singapore 2025: Enhancing Enterprise Quality and Efficiency through Cloud Resilience
CathWorks Announces Key Events for EuroPCR 2025
LILYSILK Debuts Capsule Collection Made with Liberty Fabrics, Blending British Heritage and Sustainable Silk
Visionary: Pioneering a New Era in Cancer Screening
Groundbreaking Ceremony Launches Taiwan's First Large-scale Municipal Seawater Desalination Plant
BoomerangFX Introduces LeadEngineAI™: The World's First AI Platform Revolutionizing Lead Generation, Patient Conversion, and Retention for Privat
-
ChangAn Launches Rayong Factory, Focusing on Sustainable Manufacturing, Efficiency, Cost, and Quality
The launch coincided with ChangAn's 28.59 millionth vehicle rolling off the assembly line, marking a key milestone in its international expansion. RAYONG, Thailand, May 16, 2025 /PRNewswire/ -- ChangAn Automobile ("ChangAn" or "the Company"), an intelligent low-carbon mobility technology company, officially opened its first international new energy vehicle (NEV) manufacturing base in Rayong, Thailand, integrating sustainable, low-carbon, flexible manufacturing, and intelligent digital systems that focus on efficiency, cost, and quality. The launch marks a key milestone for ChangAn in its international manufacturing structure and injects advanced intelligent manufacturing power into Thailand's automotive industry. The opening of ChangAn's Rayong Factory marks a new phase of its Vast Ocean Plan, shifting from product exports to industrial globalisation. It showcases the Company's potential in global expansion across products, smart manufacturing, branding, and green, digital innovation. As a key production hub, the plant features five intelligent workshops — including welding, painting, general and engine assembly, and battery — with 90% automation at key quality control stations, among the highest in Thailand's auto industry. The factory incorporates energy-saving and eco-friendly features aligned with green development goals. A 14MW photovoltaic system will provide 45% of the plant's electricity. Recirculating air towers, louvers, natural lighting, and rainwater recycling will cut energy use for lighting and ventilation, improve water efficiency, and lower energy costs by an estimated 5%. ChangAn has implemented an innovative and flexible production system to lower manufacturing costs and efficiently build high-value vehicles. The welding workshop features 39 robots and advanced material-joining methods, including FDS, EPS, and SPR, delivering strength beyond traditional connection techniques. The painting workshop uses 29 robots and advanced spraying to extend paint life to 15 years and reduce emissions by 40%, while the assembly line features 140 stations, including 18 fully and 125 semi-automated units. Technologies such as automated seal adjustment and AGV vehicles allow for multi-model and multi-power production. The power workshop supports engine and battery production, including ultra-precise engine tile-matching and visual guidance across 22 battery processes. Forty-five AGVs create a flexible, responsive manufacturing and transport system. As a digital-first factory, ChangAn employs a full-stack digital ecosystem with a microservice architecture for 100% online operations. The entire manufacturing process is scheduled in real time, improving supply chain coordination and reducing the order delivery cycle from 21 days to 15 days. The ChangAn Quality Operating System (CAQOS) ensures comprehensive quality management across supplier parts, vehicle production, and market services. During production, 77 surveillance cameras and 62 foolproof checkpoints are used, creating 71 quality containment processes to ensure end-to-end quality across parts, production, and market services. Looking forward, ChangAn aims to localise 80% of production at its Rayong Factory, create 30,000 jobs, and support low-carbon growth and talent development for Thailand's green transition. Positioned as a hub for Southeast Asia, Australia and New Zealand, ChangAn plans to exceed 5 million global and 3 million new energy vehicle sales by 2030. Over the next three years, it will launch 12 new energy models and expand AI features. A new Rayong parts centre will support right-hand drive markets with 24-hour delivery. "After 556 days of dedication from over 2,000 employees and partners around the world, we have built a factory that is efficient, modern, and smart," said Shen Xinghua, Managing Director of ChangAn Automobile Southeast Asia Business Unit. "We are here for the long run. Together, we will help shape a cleaner, smarter, and stronger automotive future — In Thailand , For Thailand, and For the world." Photo - https://mma.prnasia.com/media2/2689215/1.jpg?p=medium600Photo - https://mma.prnasia.com/media2/2689216/2.jpg?p=medium600
-
Gene Solutions and NEWCL Forge Strategic Partnership to Advance Genetic Testing in Taiwan
NEW TAIPEI CITY, May 16, 2025 /PRNewswire/ -- In a groundbreaking move, Gene Solutions, a leader in prenatal and oncology genetic testing, and NEWCL Biomedical Laboratory, Taiwan's pioneering clinical laboratory with LDTs certification, have joined forces to establish an advanced Next-Generation Sequencing (NGS) laboratory in Taiwan. This collaboration was sealed with the signing of a Memorandum of Understanding (MoU) at NEWCL's state-of-the-art facility in New Taipei City. Image: Dr. Nguyen Hoai Nghia, Co-founder and CEO of Gene Solutions (seated on the right), and Ms. Ku Chi-Ming, Director of NEWCL Biomedical Laboratory (seated on the left), signing the Memorandum of Understanding. Gene Solutions is set to bring its cutting-edge NIPT tests (trademarked as triSure™) and oncology tests (SPOT-MAS early cancer detection, K-TRACK, K-4CARE comprehensive genomic profiling, ctDNA-MRD monitoring) to Taiwan, expanding its footprint in the APAC region. These innovative tests, trusted by millions across Asia, will soon be available to Taiwanese patients, offering unparalleled accuracy and reliability. NEWCL, established in 2012 and part of DITECH Enterprise, is a premier biomedical laboratory located in New Taipei City. It serves major hospitals and medical service units across Taiwan, providing a wide range of bio testing services including HBV, HCV, Genotype, and Allergen Chip testing. Combining Gene Solutions' expertise in NGS test development with NEWCL's robust laboratory capabilities, this partnership aims to create one of Taiwan's most advanced NGS laboratories. This facility will cater to the growing demand for sophisticated DNA testing in prenatal care and precision oncology, ensuring Taiwanese patients have access to the latest advancements in genetic testing. With the anticipated launch of the partnered NGS lab and tech-transfer in 2025, both companies will explore the commercialization of NGS testing in Taiwan through NEWCL's established commercial network, including TUNG-BO Medical Ltd. Gene Solutions, with its strong foundation in Molecular Biology Research and Genetic Counseling, will drive scientific conferences, medical training, and research collaborations with hospitals and medical service units across Taiwan. Image: Gene Solutions and NEWCL Biomedical Laboratory during the MoU signing. In prenatal care, Gene Solutions plans to integrate its unique carrier screening (mother recessive genes) and single-gene screening (de-novo mutations of the fetus) into renowned Non-invasive Prenatal Testing (NIPT). This innovative approach has already proven successful in Southeast Asia, where over one million pregnant women have benefited from triSure tests. In oncology, the collaboration aims to bring Gene Solutions' latest Comprehensive Genomic, Transcriptomic Profiling and ctDNA Molecular Residual Disease tests K-TRACK, K-4CARE to Taiwanese medical oncologists. Currently, samples for such advanced tests must be sent overseas, which is costly and time-consuming. This partnership will eliminate these barriers, providing faster and more cost-effective solutions for cancer patients in Taiwan. Furthermore, with the commitment from NEWCL and Gene Solutions to the scientific community, oncology researchers in Taiwan will have enhanced opportunities to explore novel therapeutic biomarkers for precision oncology. Dr. Nguyen Hoai Nghia, Co-founder and CEO of Gene Solutions, expressed his enthusiasm: "We are excited to collaborate with leading partners in Asia to accelerate the adoption of cutting-edge precision healthcare technology. NEWCL's expertise in laboratory operations and DITECH's market experience will be invaluable in making these advancements accessible in Taiwan." Ms. Ku, Chi-Ming, Director of NEWCL Biomedical Laboratory, also shared: "NEWCL is thrilled to partner with Gene Solutions to bring the most advanced NGS applications to Taiwan. This collaboration marks a significant milestone in our mission to provide cutting-edge genetic testing services. By combining our laboratory excellence with Gene Solutions' innovation in prenatal and oncology diagnostics, we are poised to transform the landscape of precision medicine for patients across Taiwan." This strategic partnership is poised to transform precision healthcare in Taiwan, bringing hope and advanced solutions to patients and healthcare providers alike. About Gene Solutions Gene Solutions, a multinational biotech company, offers a comprehensive genetic testing portfolio utilizing Next-Generation Sequencing (NGS) and Artificial Intelligence algorithms. The testing services include cell-free DNA non-invasive prenatal testing (NIPT), circulating tumor DNA (ctDNA) cancer screening, genomic profiling, and treatment monitoring. Established in 2017, Gene Solutions operates a network of seven NGS laboratories, including two central CAP-accredited laboratories in Singapore and Vietnam. With over two million tests provided to patients, we remain committed to delivering accessible genetic testing services to more than 4,500 hospitals and clinics across Asia. To learn more about Gene Solutions, please visit https://genesolutions.com/ Media Contact: pr@genesolutions.com
-
ChangAn Launches Rayong Factory, Focusing on Sustainable Manufacturing, Efficiency, Cost, and Quality
The launch coincided with ChangAn's 28.59 millionth vehicle rolling off the assembly line, marking a key milestone in its international expansion. RAYONG, Thailand, May 16, 2025 /PRNewswire/ -- ChangAn Automobile ("ChangAn" or "the Company"), an intelligent low-carbon mobility technology company, officially opened its first international new energy vehicle (NEV) manufacturing base in Rayong, Thailand, integrating sustainable, low-carbon, flexible manufacturing, and intelligent digital systems that focus on efficiency, cost, and quality. The launch marks a key milestone for ChangAn in its international manufacturing structure and injects advanced intelligent manufacturing power into Thailand's automotive industry. The opening of ChangAn's Rayong Factory marks a new phase of its Vast Ocean Plan, shifting from product exports to industrial globalisation. It showcases the Company's potential in global expansion across products, smart manufacturing, branding, and green, digital innovation. As a key production hub, the plant features five intelligent workshops — including welding, painting, general and engine assembly, and battery — with 90% automation at key quality control stations, among the highest in Thailand's auto industry. The factory incorporates energy-saving and eco-friendly features aligned with green development goals. A 14MW photovoltaic system will provide 45% of the plant's electricity. Recirculating air towers, louvers, natural lighting, and rainwater recycling will cut energy use for lighting and ventilation, improve water efficiency, and lower energy costs by an estimated 5%. ChangAn has implemented an innovative and flexible production system to lower manufacturing costs and efficiently build high-value vehicles. The welding workshop features 39 robots and advanced material-joining methods, including FDS, EPS, and SPR, delivering strength beyond traditional connection techniques. The painting workshop uses 29 robots and advanced spraying to extend paint life to 15 years and reduce emissions by 40%, while the assembly line features 140 stations, including 18 fully and 125 semi-automated units. Technologies such as automated seal adjustment and AGV vehicles allow for multi-model and multi-power production. The power workshop supports engine and battery production, including ultra-precise engine tile-matching and visual guidance across 22 battery processes. Forty-five AGVs create a flexible, responsive manufacturing and transport system. As a digital-first factory, ChangAn employs a full-stack digital ecosystem with a microservice architecture for 100% online operations. The entire manufacturing process is scheduled in real time, improving supply chain coordination and reducing the order delivery cycle from 21 days to 15 days. The ChangAn Quality Operating System (CAQOS) ensures comprehensive quality management across supplier parts, vehicle production, and market services. During production, 77 surveillance cameras and 62 foolproof checkpoints are used, creating 71 quality containment processes to ensure end-to-end quality across parts, production, and market services. Looking forward, ChangAn aims to localise 80% of production at its Rayong Factory, create 30,000 jobs, and support low-carbon growth and talent development for Thailand's green transition. Positioned as a hub for Southeast Asia, Australia and New Zealand, ChangAn plans to exceed 5 million global and 3 million new energy vehicle sales by 2030. Over the next three years, it will launch 12 new energy models and expand AI features. A new Rayong parts centre will support right-hand drive markets with 24-hour delivery. "After 556 days of dedication from over 2,000 employees and partners around the world, we have built a factory that is efficient, modern, and smart," said Shen Xinghua, Managing Director of ChangAn Automobile Southeast Asia Business Unit. "We are here for the long run. Together, we will help shape a cleaner, smarter, and stronger automotive future — In Thailand, For Thailand, and For the world."
-
Global fintech CrediLinq Raises $8.5M Series A to Accelerate the Growth of B2B Embedded Finance
The round was led by OM/VC (formerly Vectr Fintech) and MS&AD Ventures. New investors include Citi North America and Rustem Family office. Returning investors include 500 Global, Epic Angels, 1982 VC, and Big Sky Capital. CrediLinq operates in the embedded finance sector, enabling B2B platforms to offer financing solutions. Its AI-powered technology infrastructure integrates into online platforms through APIs and leverages the platform's real time alternative data to provide credit seamlessly to SMEs at the point of need. Funds will be deployed to drive market expansion, strategic acquisitions and partnerships in the US, UK and Australia; boost local presence in Singapore; hire senior commercial, product and tech talent and invest in further technology enhancements. SINGAPORE, May 16, 2025 /PRNewswire/ -- CrediLinq, the AI-powered embedded finance platform that is revolutionizing access to growth capital for underserved digital-first SMEs globally, announced today the close of its USD $8.5 million Series A funding round. The round was led by OM/VC and MS&AD Ventures. New investors include Citi North America and Rustem Family office. Returning investors include 500 Global, Epic Angels, 1982 VC and Big Sky Capital. CrediLinq will immediately accelerate geographic expansion, starting with the United States and subsequently into the United Kingdom and Australia. The company will look to partner with larger digital platforms in these markets to drive user growth, enabling digitally native businesses transacting on platforms to access capital. In addition, CrediLinq will strengthen its leadership bench in sales, marketing, product and tech to support expansion in the target markets. A significant portion of the funds will also be invested in enhancing the company's technology stack — with continual improvement of AI-led credit algorithms that use the SME's real-time digital footprint including platform data, unstructured data, bureau information and the like, to reduce non-performing loans (NPLs), improve 'Default On' collections, and build agentic workflows to drive efficiency. Deep Singh, Founder and Group CEO of CrediLinq, remarked: "Today marks a pivotal moment for CrediLinq as we accelerate the growth of embedded finance globally, helping platforms empower digital native SMEs with flexible, transparent and more seamless access to capital. With this new funding, we are excited to deepen our partnerships, expand into new markets, and invest in senior talent and technology infrastructure that will support the next phase of our growth." Vikram Kotibhaskar, Co-Founder of CrediLinq. added: "The embedded credit revolution continues to gain momentum, and CrediLinq is at the forefront of this innovation. By being integrated within platforms, our Credit-as-a-Service stack leverages API connectivity, transactional data and credit algorithms for quick decision-making at the point of need and offers easy checkout within the partner ecosystem. This results in a fast, frictionless and transparent customer experience and more ways for platforms to monetize their business. Our agentic workflows also drive efficiency and continuous monitoring to keep loan losses low. Platform partners benefit with higher stickiness, trust, and scalability that drives up GMV." CrediLinq Co-founders, Deep Singh (right) and Vikram Kotibhaskar (left) (Photo credit: CrediLinq) CrediLinq's solutions can be embedded across platforms that cover verticals of procurement, supply chain, e-commerce marketplaces, freelance platforms, banking, accounting, and payments. In the e-commerce space for example, CrediLinq has integrations with key marketplaces such as Amazon, Lazada and TikTok Shop. Mark Munoz, Managing Partner at OM/VC commented: "As a long-term investor in Credilinq, we're proud to support their growth into a global leader in credit-as-a-service. Their innovative use of technologies like AI to drive positive revenue outcomes for clients is aligned with our investment philosophy. It's also encouraging to see that many of its users have reported consistent, immediate ROI from their crediting platforms, underscoring the value that Credilinq is delivering at scale." Lee Smallwood, Global Head of Markets Innovation & Investments at Citi, said: "CrediLinq's innovative approach to embedded finance leverages AI to provide seamless credit solutions for digital-first SMEs, which complements our goal to transform financial services. Their platform's ability to integrate into diverse digital ecosystems positions them to make a significant impact globally." Jon Soberg, Managing Partner at MS&AD Ventures, mentioned: "CrediLinq's AI-driven platform offers a scalable solution to B2B platforms that want to embed lending as a complementary, value-add offering. Their focus on embedding credit within digital workflows is exactly what today's rapidly evolving digital economy demands." Vishal Harnal, Managing Partner at 500 Global, reflected: "We first backed CrediLinq in 2022 and are doubling down as they scale their AI-powered platform globally. Deep and his team bring exceptional domain expertise and execution, having already built a trusted, scalable model for embedded finance that allows them to expand beyond Southeast Asia." The CrediLinq team (Photo credit: CrediLinq) For more information about CrediLinq's embedded finance platform and Series A milestones, please visit www.credilinq.ai. About CrediLinq CrediLinq is a technology infrastructure company with a proprietary Credit-as-a-Service stack. Their API-centric approach enables B2B platforms and banks to build financial products for merchants, enabling the financial empowerment of underserved digital native SMEs to build, grow and scale their business. What sets CrediLinq apart is embedding lending solutions within these platforms and harnessing the platform's real-time alternative data, to offer business owners swift access to funding through AI-driven credit decisioning and agentic workflows. This empowers SMEs to manage cash flow by accessing seamless, flexible and transparent lending options. The company holds a Capital Markets Services License under the Monetary Authority of Singapore (MAS), enabling it to raise and deploy institutional capital to support SME growth. CrediLinq is ISO 27001 certified for information security management and is a member of the Singapore Fintech Association. About Citi Citigroup (NYSE: C), a leading global bank, invests in and partners with innovative startups that are transforming financial services and other industries. Focus areas include fintech, data analytics, and enterprise solutions. For more information, visit https://www.citi.com. About OM/VC OMVC is an early-stage venture capital firm targeting investment opportunities in fintech, deep tech, climate tech and where they intersect. With presence in San Francisco, Honolulu, New York and Singapore, it deploys private capital across Seed to Series A companies and provides visionary founders with operating expertise, capital formation advisory and access to talent. Founded by a former entrepreneur and a regulatory innovator, OMVC aims to create value on behalf of its investors, portfolio companies and the communities it operates in through integrating human-centric and tech-forward approaches. For more information, please visit: omvc.co. About MS&AD Ventures MS&AD Ventures is the corporate venture capital arm of MS&AD Insurance Group Holdings, one of the world's largest insurance groups. MS&AD Ventures invests in early-stage startups advancing innovation across insurtech, fintech, and ESG sectors. For more information, visit https://msad.vc/. About 500 Global 500 Global is a venture capital firm with US$2.2 billion in assets under management (as of 31 December 2024) investing in globally ambitious founders building fast-growing technology companies. The company focuses on the U.S. and global markets where innovation, capital, and ecosystems can propel startups and unlock long-term value. For more details, visit https://500.co/. Multimedia Links CrediLinq Company Overview CrediLinq LinkedIn Page [Founder Profiles: Deep Singh | Vikram Kotibhaskar]
-
Modlily Celebrates Self-Love and Female Empowerment with Stylish Swimwear for Women of All Ages
LOS ANGELES, May 16, 2025 /PRNewswire/ -- Modlily, a leading swimwear brand dedicated to designing comfortable, casual, and cost-effective swimsuits for older women, continues to redefine confidence and style with its latest collections. From chic tankinis to bold bikinis, Modlily's designs embrace self-love and empower women's values, ensuring every woman feels beautiful and confident at any age. Innovative Designs with a Woman's Touch For over a decade, Modlily's all-female design team has crafted swimwear that blends functionality with stunning aesthetics. Understanding the unique needs of mature women, the brand offers swimsuits that provide both comfort and style. The tankini swimwear, a Modlily favorite, delivers the perfect balance of coverage and freedom, while their bikini collections challenge stereotypes, proving that beauty and confidence are ageless. Eco-Friendly Fashion with a Purpose Modlily is committed to sustainability, adhering to eco-friendly practices without compromising on style. Each piece is thoughtfully designed to empower women, encouraging them to embrace their bodies and celebrate their individuality. By prioritizing high-quality fabrics and original patterns, Modlily ensures that every swimsuit not only looks spectacular but also aligns with the values of modern, conscious consumers. Self-Love and Confidence at Every Stage At the heart of Modlily's mission is the belief that swimwear should inspire self-love andconfidence. The brand's inclusive approach caters to diverse body types, helping women feel empowered and valued. Whether lounging by the pool or enjoying a beach getaway, Modlily's swimsuits are designed to make women feel their best. With consistently high ratings and a loyal customer base, Modlily continues to set the standard for affordable, stylish, and empowering swimwear. Explore the latest collections and join the movement of confidence and female empowerment at https://www.modlily.com/.
-
Blending Innovation with Tradition: Thailand Brings Holistic Wellness to Expo 2025
BANGKOK, May 16, 2025 /PRNewswire/ -- Within just the first month of Expo 2025 in Osaka, Japan, the Thai Pavilion has welcomed over 200,000 visitors charmed by Thailand's fusion of cutting-edge innovation and rich cultural heritage. Visitors come to explore the Thai Pavilion at Expo 2025 Osaka. Located in the Connecting Lives Zone (A13), the Thai Pavilion quickly became one of the most-photographed spots at the Expo. The striking design optimizes a narrow, elongated space. A roof inspired by traditional Thai architecture forms half of a classic gable, while the neighboring glass-walled building completes the visual story. The architectural harmony symbolizes the pavilion's theme—blending the old with the new. "At Osaka Expo 2025, Thailand aims to showcase our exceptional potential and demonstrate our wisdom in shaping a better life and society. As such, our country will participate under the theme "Connecting Lives for Greatest Happiness", showcasing how Thai happiness is deeply rooted in our way of life, culture, arts, wisdom, and—most importantly—our renowned hospitality. To illustrate this, we will highlight Thailand's expertise in healthcare services, which have evolved into a world-class Medical and Wellness Hub—a perfect blend of art and science. Our pavilion will showcase one of Thailand's greatest Soft Power assets: the integration of medical service with Traditional Thai health and wellness practices. This will further demonstrate Thailand's potential as a global leader in health and wellness, driving new economic opportunities for the country in both the short and long term," said Prime Minister Paetongtarn Shinawatra. Prime Minister Paetongtarn Shinawatra proudly poses with “BHUMI JAI,” the official mascot of the Thailand Pavilion at Expo 2025 Osaka. The fusion of Thai wisdom and wellness innovation is at the heart of the Thai Pavilion. Visitors can experience this through zones: Thai Wisdom of Immunity, Thai Medical & Wellness, and the Thai Living Lab. Upon entering the Thai Pavilion, visitors will enjoy a short welcoming film, Wisdom of Life, showcasing Thailand's wellness culture through five pillars: food, film, fashion, fighting, and festivals. Vibrant performances and artistic visuals highlight Thailand's transformation into a "Fortress of Health" and a gateway to immunity. With state-of-the-art health and wellness technologies, innovation takes center stage in the Thai Medical & Wellness zone. Thailand is positioning itself as a leader in medical advancements and pharmaceutical manufacturing in Asia. One standout innovation is Dinsaw Mini AI, a smart robot designed to assist the elderly, children, and patients. It provides 24/7 monitoring, communicates with doctors, and supports memory and cognitive functions. This robot is easing caregiving burdens and enhancing quality of life. Other featured innovations include: Space Dynamic Prosthetic Foot – A dynamic carbon fiber prosthetic designed for natural movement, ideal for walking and running. Titanium Cranial Mesh – A 3D-printed, US FDA-certified implant that is lightweight and strong, offering life-changing medical support. Herbble Sprays – Herbal mouth and nasal sprays made from kale, scientifically shown to reduce the accumulation of Influenza A and RSV viruses. The Wisdom for Healing After exploring the high-energy Expo, visitors find tranquility in the Thai Living Lab zone—a serene space offering wellness workshops. Guests can experience traditional Thai massage, explore herbal compresses and spa product-making, and delve into the sensory richness of Thai herbs. Monthly workshops rotate themes—from aromatherapy sachets to Thai-style fitness and food therapy. Food is Medicine Food lovers flock to the interactive Thai kitchen to learn to make Tom Yum Goong, while discovering the health benefits hidden in every spicy spoonful. Visitors also enjoy cooking demonstrations that highlight the healing wisdom behind Thai cuisine. Warm Smiles, Lasting Memories The spirit of Thai hospitality fills the air, reflected in the warm smile of the staff, and fun Thai language lessons that connect people through culture and kindness. Don't miss your chance to explore the Thai Pavilion at Expo 2025 in Osaka, Kansai, Japan, from April 13 to October 13, 2025. Step into a world where ancient healing meets future-forward innovation—and be inspired by how Thailand's wellness wisdom is ready to be part of a healthier, more connected world.  
-
DHL transforms DHL Health Logistics campus in Florstadt into a European pharmaceutical hub
DHL Group is moving forward with the strategic expansion of its Life Sciences & Healthcare (LSH) campus in Florstadt near Frankfurt am Main, Germany. The site’s transformation into a European pharmaceutical hub is part of a global multibillion investment in DHL Health Logistics. With the addition of the fourth new state-of-the-art logistics center, the campus now comprises a total of 100,000 square meters of warehouse space. With a footprint in excess of 14 soccer fields, the DHL site will in future offer capacity for more than 140,000 pallets for pharmaceutical and medical products, serving international customers from the biopharma, specialty pharma, medical technology and clinical research sectors with more than 600 highly qualified employees on site. The new climate-neutral “Florstadt 4” warehouse spans over 30,000 square meters and has been specifically designed for the storage and distribution of high-value pharmaceutical and medical products. It features multiple temperature zones, with the capability to reach as low as -70°C if needed. Particular focus is placed on the critical temperature ranges of 2–8°C and -20°C, ensuring compliance with the highest standards for handling temperature-sensitive products. With its four highly specialized warehouses right in the geographical heart of Central Europe, the site offers ideal logistics connections and first-class infrastructure for the storage and distribution of sophisticated pharmaceutical and medical products. In addition, highly specialized services such as sample collection, support for clinical studies and the handling of biopharmaceuticals and cell and gene therapies are provided on site. A further special feature on the premises is the integrated clean room which enables GMP-compliant processes for highly sensitive substances and raw pharmaceutical materials. This includes the handling of solid and liquid hazardous substances up to 1,000 liters – including active pharmaceutical ingredients (API) and samples of active ingredients as well as analytical and microbiological tests. The clean room adheres to the most stringent European and international pharmaceutical standards and is an outstanding example of the advanced logistics solutions that DHL offers its customers. With this further expansion phase, the Florstadt site is also consolidating its strategic importance within the global DHL Health Logistics network. "With this fourth expansion, we are creating capacity for the future in Florstadt,” says Hendrik Venter, CEO DHL Supply Chain for Europe, Middle East and Africa. From here, we can supply customers not only in Germany, but throughout Europe – and beyond. Our central location in the Frankfurt economic region, right in the heart of Europe, the close proximity to Frankfurt Airport and the strong local infrastructure all make Florstadt a key location for our activities and our ambitious growth agenda in the Life Science & Healthcare sector," he confirms. In his extended role as the Executive Board Member responsible for the DHL Health Logistics sector brand, Oscar de Bok, Global CEO DHL Supply Chain, sees the expansion of the Florstadt site as consistent with DHL Group’s overall strategic focus: "Florstadt 4 is a prime and concrete example of how we are implementing our Strategy 2030 – with investments totaling €2 billion by 2030, we are strengthening our global DHL Health Logistics network. Hubs like this one here in Florstadt near Frankfurt form the backbone of our end-to-end Supply Chain solutions, which we are increasingly offering customers from a single source. We are creating state-of-the-art, resilient supply chains for the next generation of therapies – from biopharma to cell and gene therapy. Our mission is to provide patients with the vital medicines they need, when they need them, all around the world.” At the Florstadt site, DHL Supply Chain is focusing on end-to-end visibility, compliance, and digitalization – with daily operational processes supported by a warehouse management system that is closely integrated with the customer’s IT systems. This also facilitates efficient supply chain management for particularly complex and patient-specific products such as clinical trials or temperature-sensitive specialty medications. Rainer Haag, CEO DHL Supply Chain Germany & Alps, confirms the importance of the location: "The Frankfurt Rhine-Main area is one of the most important economic regions in Europe. The fact that we are consistently expanding our largest LSH campus in Germany right here in Florstadt shows just how important the site is at the heart of our DHL Health Logistics strategy. As we expand, we are keeping an eye to sustainability and climate protection – the site is also a flagship project in terms of environmentally friendly operations.” With climate-neutral operations, solar thermal panels, air source heat pumps and a comprehensive energy concept with LED lighting control and a photovoltaic system, DHL is pursuing a holistic approach as a Green Logistics Provider of Choice. The site’s DGNB Gold certification confirms these high environmental standards and the future-oriented planning of the project.
-
Yatsen Announces First Quarter 2025 Financial Results and Provides Updates on Share Repurchase Program
Conference Call to Be Held at 7:30 A.M. U.S. Eastern Time on May 16, 2025 GUANGZHOU, China, May 16, 2025 /PRNewswire/ -- Yatsen Holding Limited ("Yatsen" or the "Company") (NYSE: YSG), a leading China-based beauty group, today announced its unaudited financial results for the first quarter ended March 31, 2025 and provided updates on share repurchase program. First Quarter 2025 Highlights Total net revenues for the first quarter of 2025 increased by 7.8% to RMB833.5 million (US$114.9 million) from RMB773.4 million for the prior year period. Total net revenues from Skincare Brands[1] for the first quarter of 2025 increased by 47.7% to RMB362.4 million (US$49.9 million) from RMB245.3 million for the prior year period. As a percentage of total net revenues, total net revenues from Skincare Brands for the first quarter of 2025 were 43.5%, as compared with 31.7% for the prior year period. Gross margin for the first quarter of 2025 increased to 79.1% from 77.7% for the prior year period. Net loss for the first quarter of 2025 narrowed by 95.5% to RMB5.6 million (US$0.8 million) from RMB124.9 million for the prior year period. Non-GAAP net income[2] for the first quarter of 2025 was RMB7.1 million (US1.0 million), as compared with non-GAAP net loss of RMB83.8 million for the prior year period. Mr. Jinfeng Huang, Founder, Chairman and Chief Executive Officer of Yatsen, stated, "We began 2025 with results in line with our guidance. Despite ongoing softness in the beauty market, we delivered a 7.8% year-over-year increase in total net revenues. Notably, net revenues from our skincare brands grew by 47.7% year over year, with the combined net revenues of our three major skincare brands, Galénic, DR.WU and Eve Lom, growing by 58.0%. This solid performance reflects our continued focus on new product development, R&D and brand building. We remain confident in our ability to execute our strategic transformation plan aimed at sustainable growth, and we look forward to the opportunities that lie ahead for the remainder of the year." Mr. Donghao Yang, Director and Chief Financial Officer of Yatsen, commented, "We are pleased to report meaningful improvements in both net revenues and loss position for the first quarter of 2025. Total net revenues grew by 7.8% year over year, and gross margin increased to 79.1%, up from 77.7% for the prior year period. While we recorded a net loss of RMB5.6 million, significantly narrowed from RMB124.9 million a year ago, we achieved non-GAAP net income of RMB7.1 million, as compared with non-GAAP net loss of RMB83.8 million for the same period last year. With cash and short-term investments of RMB1.28 billion, we have sufficient resources to advance our strategic plan going forward." First Quarter 2025 Financial Results Net Revenues Total net revenues for the first quarter of 2025 increased by 7.8% to RMB833.5 million (US$114.9 million) from RMB773.4 million for the prior year period. The increase was primarily due to a 47.7% year-over-year increase in net revenues from Skincare Brands, partially offset by a 9.9% year-over-year decrease in net revenues from Color Cosmetics Brands.[3] Gross Profit and Gross Margin Gross profit for the first quarter of 2025 increased by 9.7% to RMB659.1 million (US$90.8 million) from RMB600.9 million for the prior year period. Gross margin for the first quarter of 2025 increased to 79.1% from 77.7% for the prior year period. The increase was primarily driven by an increase in sales of higher-gross-margin products. Operating Expenses Total operating expenses for the first quarter of 2025 decreased by 8.6% to RMB693.2 million (US$95.5 million) from RMB758.7 million for the prior year period. As a percentage of total net revenues, total operating expenses for the first quarter of 2025 were 83.2%, as compared with 98.1% for the prior year period. Fulfillment Expenses. Fulfillment expenses for the first quarter of 2025 were RMB51.8 million (US$7.1 million), as compared with RMB51.4 million for the prior year period. As a percentage of total net revenues, fulfillment expenses for the first quarter of 2025 decreased to 6.2% from 6.7% for the prior year period. The decrease was primarily due to further improvements in logistics efficiency. Selling and Marketing Expenses. Selling and marketing expenses for the first quarter of 2025 were RMB553.8 million (US$76.3 million), as compared with RMB539.2 million for the prior year period. As a percentage of total net revenues, selling and marketing expenses for the first quarter of 2025 decreased to 66.4% from 69.7% for the prior year period. The decrease was primarily due to the Company's more strategic marketing spending, combined with the selective closure of offline stores. General and Administrative Expenses. General and administrative expenses for the first quarter of 2025 were RMB64.9 million (US$8.9 million), as compared with RMB140.1 million for the prior year period. As a percentage of total net revenues, general and administrative expenses for the first quarter of 2025 decreased to 7.8% from 18.1% for the prior year period. The decrease was primarily attributable to lower share-based compensation expenses as a result of using the graded-vesting method over the vesting term of the Company's awards and lower payroll expenses resulting from a reduction in general and administrative headcount. Research and Development Expenses. Research and development expenses for the first quarter of 2025 were RMB22.6 million (US$3.1 million), as compared with RMB27.9 million for the prior year period. As a percentage of total net revenues, research and development expenses for the first quarter of 2025 decreased to 2.7% from 3.6% for the prior year period. The decrease was primarily due to lower lease expenses resulting from more favorable terms under a lease agreement renegotiated during the first quarter of 2025 and lower share-based compensation expenses. Loss from Operations Loss from operations for the first quarter of 2025 was RMB34.1 million (US$4.7 million), as compared with RMB157.7 million for the prior year period. Operating loss margin was 4.1%, as compared with 20.4% for the prior year period. Non-GAAP loss from operations[4] for the first quarter of 2025 was RMB14.9 million (US$2.0 million), as compared with non-GAAP loss from operations of RMB107.0 million for the prior year period. Non-GAAP operating loss margin[5] was 1.8%, as compared with non-GAAP operating loss margin of 13.8% for the prior year period. Net Loss / Income Net loss for the first quarter of 2025 was RMB5.6 million (US$0.8 million), as compared with RMB124.9 million for the prior year period. Net loss margin was 0.7%, as compared with 16.1% for the prior year period. Net loss attributable to Yatsen's ordinary shareholders per diluted ADS[6] for the first quarter of 2025 was RMB0.06 (US$0.01), as compared with RMB1.16 for the prior year period. Non-GAAP net income for the first quarter of 2025 was RMB7.1 million (US$1.0 million), as compared with non-GAAP net loss of RMB83.8 million for the prior year period. Non-GAAP net income margin was 0.9%, as compared with non-GAAP net loss margin of 10.8% for the prior year period. Non-GAAP net income attributable to Yatsen's ordinary shareholders per diluted ADS[7] for the first quarter of 2025 was RMB0.07 (US$0.01), as compared with non-GAAP net loss attributable to Yatsen's ordinary shareholders per diluted ADS of RMB0.78 for the prior year period. Balance Sheet and Cash Flow As of March 31, 2025, the Company had cash and short-term investments of RMB1.28 billion (US$176.4 million), as compared with RMB1.36 billion as of December 31, 2024. Net cash generated from operating activities for the first quarter of 2025 was RMB23.8 million (US$3.3 million), as compared with net cash used in operating activities of RMB121.8 million for the prior year period. Business Outlook For the second quarter of 2025, the Company expects its total net revenues to be between RMB810.4 million and RMB889.9 million, representing a year-over-year increase of approximately 2% to 12%. These forecasts reflect the Company's current and preliminary views on the market and operational conditions, which are subject to change. Updates on Share Repurchase Program As previously announced in November 2021, August 2022 and November 2023, the Company established and subsequently modified a share repurchase program under which the Company may repurchase up to US$200.0 million worth of its ordinary shares (including in the form of ADSs) through November 19, 2025 (the "Existing Share Repurchase Program"). From the launch of the Existing Share Repurchase Program on November 17, 2021 through May 15, 2025, the Company in aggregate purchased approximately 39.8 million ADSs for a total consideration of approximately US$199.9 million (inclusive of broker commissions) under the Existing Share Repurchase Program. On May 16, 2025, the Company's board of directors approved a new share repurchase program (the "2025 Share Repurchase Program"), under which the Company may repurchase up to US$30.0 million worth of its ordinary shares (including in the form of ADSs) over the following 24 months commencing on May 16, 2025. The share repurchases may be effected from time to time on the open market at prevailing market prices, in privately negotiated transactions, in block trades and/or through other legally permissible means, depending on market conditions and will be implemented in accordance with all applicable rules and regulations. The Company's board of directors will review the 2025 Share Repurchase Program periodically, and may authorize adjustments to its terms and size. The Company expects to fund the repurchases with its existing cash balance. Exchange Rate This announcement contains translations of certain Renminbi ("RMB") amounts into U.S. dollars ("US$") at specified rates solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to US$ were made at a rate of RMB7.2567 to US$1.00, the exchange rate in effect as of March 31, 2025, as set forth in the H.10 statistical release of The Board of Governors of the Federal Reserve System. The Company makes no representation that any RMB or US$ amounts could have been, or could be, converted into US$ or RMB, as the case may be, at any particular rate, or at all. [1] Include net revenues from Galénic, DR.WU (its mainland China business), Eve Lom and other skincare brands of the Company. [2] Non-GAAP net income (loss) is a non-GAAP financial measure. Non-GAAP net income (loss) is defined as net income (loss) excluding (i) share-based compensation expenses, (ii) amortization of intangible assets resulting from assets and business acquisitions, (iii) revaluation of investments on the share of equity method investments, (iv) impairment of goodwill and (v) tax effects on non-GAAP adjustments. [3] Include Perfect Diary, Little Ondine, Pink Bear and other color cosmetics brands of the Company. [4] Non-GAAP loss from operations is a non-GAAP financial measure. Non-GAAP loss from operations is defined as loss from operations excluding (i) share-based compensation expenses, (ii) amortization of intangible assets resulting from assets and business acquisitions and (iii) impairment of goodwill. [5] Non-GAAP operating loss margin is a non-GAAP financial measure, which is defined as non-GAAP net loss from operations as a percentage of total net revenues. [6] ADS refers to American depositary shares, each of which represents twenty Class A ordinary shares. [7] Non-GAAP net income (loss) attributable to ordinary shareholders per diluted ADS is a non-GAAP financial measure. Non-GAAP net income (loss) attributable to ordinary shareholders per diluted ADS is defined as non-GAAP net income (loss) attributable to ordinary shareholders divided by the weighted average number of diluted ADS outstanding for computing diluted earnings per ADS. Non-GAAP net income (loss) attributable to ordinary shareholders is defined as net income (loss) attributable to ordinary shareholders excluding (i) share-based compensation expenses, (ii) amortization of intangible assets resulting from assets and business acquisitions, (iii) revaluation of investments on the share of equity method investments, (iv) impairment of goodwill, (v) tax effects on non-GAAP adjustments and (vi) accretion to redeemable non-controlling interests. Conference Call Information The Company's management will hold a conference call on Friday, May 16, 2025, at 7:30 A.M. U.S. Eastern Time or 7:30 P.M. Beijing Time to discuss its financial results and operating performance for the first quarter of 2025. United States (toll free): +1-888-346-8982 International: +1-412-902-4272 Mainland China (toll free): 400-120-1203 Hong Kong, SAR (toll free): 800-905-945 Hong Kong, SAR: +852-3018-4992 The replay will be accessible through Friday, May 23, by dialing the following numbers: United States: +1-877-344-7529 International: +1-412-317-0088 Replay Access Code: 1147723 A live and archived webcast of the conference call will also be available on the Company's investor relations website at http://ir.yatsenglobal.com. About Yatsen Holding Limited Yatsen Holding Limited (NYSE: YSG) is a leading China-based beauty group with the mission of creating an exciting new journey of beauty discovery for consumers around the world. Founded in 2016, the Company has launched and acquired numerous color cosmetics and skincare brands including Perfect Diary, Little Ondine, Pink Bear, Galénic, DR.WU (its mainland China business), Eve Lom and EANTiM. The Company's flagship brand, Perfect Diary, is one of the leading color cosmetics brands in China in terms of retail sales value. The Company primarily reaches and engages with customers directly both online and offline, with expansive presence across all major e-commerce, social and content platforms in China. For more information, please visit http://ir.yatsenglobal.com. Use of Non-GAAP Financial Measures The Company uses non-GAAP income (loss) from operations, non-GAAP operating income (loss) margin, non-GAAP net income (loss), non-GAAP net income (loss) margin, non-GAAP net income (loss) attributable to ordinary shareholders and non-GAAP net income (loss) attributable to ordinary shareholders per diluted ADS, each a non-GAAP financial measure, in reviewing and assessing its operating performance. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with U.S. GAAP. The Company presents these non-GAAP financial measures because they are used by the management to evaluate operating performance and formulate business plans. Non-GAAP financial measures help identify underlying trends in its business, provide further information about its results of operations, and enhance the overall understanding of its past performance and future prospects. The Company defines non-GAAP income (loss) from operations as income (loss) from operations excluding (i) share-based compensation expenses, (ii) amortization of intangible assets resulting from assets and business acquisitions and (iii) impairment of goodwill. Non-GAAP operating income (loss) margin is non-GAAP income (loss) from operations as a percentage of total net revenues. The Company defines non-GAAP net income (loss) as net income (loss) excluding (i) share-based compensation expenses, (ii) amortization of intangible assets resulting from assets and business acquisitions, (iii) revaluation of investments on the share of equity method investments, (iv) impairment of goodwill and (v) tax effects on non-GAAP adjustments. Non-GAAP net income (loss) margin is non-GAAP net income (loss) as a percentage of total net revenues. The Company defines non-GAAP net income (loss) attributable to ordinary shareholders as net income (loss) attributable to ordinary shareholders excluding (i) share-based compensation expenses, (ii) amortization of intangible assets resulting from assets and business acquisitions, (iii) revaluation of investments on the share of equity method investments, (iv) impairment of goodwill, (v) tax effects on non-GAAP adjustments and (vi) accretion to redeemable non-controlling interests. Non-GAAP net income (loss) attributable to ordinary shareholders per diluted ADS is computed using non-GAAP net income (loss) attributable to ordinary shareholders divided by weighted average number of diluted ADS outstanding for computing diluted earnings per ADS. However, the non-GAAP financial measures have limitations as analytical tools as the non-GAAP financial measures are not presented in accordance with U.S. GAAP and may differ from the non-GAAP information used by other companies, including peer companies, and therefore their comparability may be limited. The Company compensates for these limitations by reconciling the non-GAAP financial measures to the nearest U.S. GAAP performance measure, all of which should be considered when evaluating performance. The Company encourages investors and others to review its financial information in its entirety and not rely on a single financial measure. Reconciliations of Yatsen's non-GAAP financial measure to the most comparable U.S. GAAP measure are included at the end of this press release. Safe Harbor Statement This announcement contains statements that may constitute "forward-looking" statements which are made pursuant to the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "aims," "future," "intends," "plans," "believes," "estimates," "likely to," and similar statements. The Company may also make written or oral forward-looking statements in its periodic reports to the Securities and Exchange Commission ("SEC"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company's beliefs, plans, outlook and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company's growth strategies; its future business development, results of operations and financial condition; its ability to continue to roll out popular products and maintain popularity of existing products; its ability to anticipate and respond to changes in industry trends and consumer preferences and behavior in a timely manner; its ability to attract and retain new customers and to increase revenues generated from repeat customers; its expectations regarding demand for and market acceptance of its products and services; its ability to integrate newly-acquired businesses and brands; trends and competition in and relevant government policies and regulations relating to China's beauty market; changes in its revenues and certain cost or expense items; and general economic conditions globally and in China. Further information regarding these and other risks is included in the Company's filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law. For investor and media inquiries, please contact: Yatsen Holding LimitedInvestor RelationsE-mail: ir@yatsenglobal.com YATSEN HOLDING LIMITED UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (All amounts in thousands, except for share, per share data or otherwise noted) December 31, March 31, March 31, 2024 2025 2025 RMB'000 RMB'000 USD'000 Assets Current assets Cash and cash equivalents 817,395 669,776 92,298 Short-term investments 539,130 610,147 84,081 Accounts receivable, net 214,558 199,892 27,546 Inventories, net 386,054 383,352 52,827 Prepayments and other current assets 381,404 374,849 51,656 Amounts due from related parties 9,113 2,553 352 Total current assets 2,347,654 2,240,569 308,760 Non-current assets Investments 664,579 668,081 92,064 Property and equipment, net 74,373 69,695 9,604 Goodwill, net 155,029 155,029 21,364 Intangible assets, net 559,708 562,240 77,479 Deferred tax assets 1,381 1,417 195 Right-of-use assets, net 147,501 159,422 21,969 Other non-current assets 20,642 20,954 2,888 Total non-current assets 1,623,213 1,636,838 225,563 Total assets 3,970,867 3,877,407 534,323 Liabilities, redeemable non-controlling interests and shareholders' equity Current liabilities Accounts payable 72,090 74,680 10,291 Advances from customers 19,574 20,698 2,852 Accrued expenses and other liabilities 460,143 344,559 47,481 Amounts due to related parties 28,884 30,037 4,139 Income tax payables 20,088 16,985 2,341 Lease liabilities due within one year 39,409 39,348 5,422 Total current liabilities 640,188 526,307 72,526 Non-current liabilities
-
From Affordable Premiums to Holistic Care, Policybazaar Unveils Comprehensive Solutions for NRIs and Their Families in India
GURUGRAM, India, May 16, 2025 /PRNewswire/ -- Policybazaar, one of India's largest online insurance platforms, has launched, through its insurance partners, a comprehensive suite of initiatives tailored to the needs of Non-Resident Indians (NRIs) and their families residing in India. Why NRIs are Turning to Indian Health Insurance An increasing number of NRIs are opting for health insurance in India, not just for their families but also for themselves. This is because India offers an attractive value proposition. Health insurance premiums are at least 35% lower than in countries like the USA, Canada, Gulf nations, or Europe. Additionally, medical procedures, medicines, and consultations in India cost 70% to 90% less than in most Western countries, making high-quality care accessible at a fraction of the cost. Exclusive Financial Benefits for NRIs To further ease the financial burden, Policybazaar, in collaboration with leading insurance partners, is offering NRI-specific benefits such as: Up to 40% Discounts on Premiums: Available to NRIs who maintain a no-claim status upon submission of valid documentation like a passport and proof of international residence. 18% GST Refund: Applicable for annual premiums paid via NRE accounts, subject to necessary KYC, address, and banking documentation. Multi-Year and Annual Policy Savings: Discounts of up to 15% reward long-term policy commitments. Lower Overall Premiums: Indian health plans sold via Policybazaar are, on average, 35% more cost-effective than similar offerings in the GCC, USA, Canada, and UK. NRI Care Program, A Trusted Lifeline for Elderly Parents For NRIs deeply concerned about the health and well-being of ageing parents back home, Policybazaar has introduced the NRI Care Program in partnership with top insurers. This service is designed to provide personalised and dependable support, including: 24/7 Emergency Helpline and Claims Assistance: A rapid-response setup ensures timely support in urgent situations. Hospitalisation Coordination: Concierge-like services to manage hospital admissions, documentation, and discharge. Doctor-on-Call and OPD Coverage: Timely medical guidance, minor treatments, and follow-ups without needing hospitalisation. Wellness & Emotional Support: Tools and resources to maintain seniors' mental and emotional well-being, addressing isolation and inactivity. Fast-Track Claims Processing: On-ground assistance is provided within 30 minutes during emergencies, offering NRIs peace of mind that their loved ones are never left unsupported. "Our endeavour is to ease the dual burden NRIs often face, managing their lives abroad while ensuring their families in India are financially protected and well cared for," said Sarbvir Singh, Joint Group CEO, PB Fintech. About Policybazaar As one of India's largest insurance brokers, Policybazaar is committed to making insurance accessible, transparent, and personalised for every Indian and global customer. Since 2008, Policybazaar has empowered over 80.5 million registered users, issued 49.3 million policies, and helped protect 9 million families against death, disease, and disability. All discounts are provided by insurers as per IRDAI approved insurance plans. T&C Apply. Contact:Simran Bhatia, simranbhatia@policybazaar.com Logo: https://mma.prnasia.com/media2/2689166/Policybazaar_Logo.jpg?p=medium600
-
Genome & Company's Skincare Brand UIQ Expands into North America with Official Amazon Brand Store Launch
Official debut signals full-scale entry into global markets Biome Barrier Cream Mist earns 'Amazon's Choice' designation SEOUL, South Korea, May 16, 2025 /PRNewswire/ -- Genome & Company, a global clinical-stage biotechnology firm, has officially launched its skincare brand UIQ (www.theuiq.com) on Amazon, the largest e-commerce platform in the United States. Genome & Company’s Skincare Brand UIQ Expands into North America with Official Amazon Brand Store Launch UIQ, renowned for its patented skin-derived microbiome ingredients targeting a range of skin concerns, aims to solidify its North American presence by leveraging Amazon's expansive platform and enhancing direct engagement with global consumers. Through its dedicated Amazon brand store, UIQ now offers signature products including Biome Barrier Cream Mist (100ml) and Biome Barrier Collagen Firming Cleansing Balm (100ml). These hero products—part of the Biome Barrier, Biome Remedy, and Biome C collections—exemplify the brand's commitment to science-backed, targeted skincare solutions. Notably, the Biome Barrier Cream Mist was awarded the Amazon's Choice badge shortly after launch, in recognition of its superior quality, user reviews, and fulfillment performance. UIQ also reported outstanding performance during its first participation in Amazon's Spring Sale (March 25–31, local time). As of 5:00 PM KST on April 1, sales had surged by approximately 1,900% compared to its average daily revenue—demonstrating significant growth potential in the U.S. market. Customer feedback on Amazon has been overwhelmingly favorable, underscoring the product's efficacy and consumer appeal. Many reviewers praised the mist for being "glow-boosting without feeling heavy" and expressed enthusiasm for "discovering a K-beauty brand genuinely committed to skin science." This successful debut is regarded as a strategic milestone in UIQ's global expansion roadmap. To further strengthen connections with international consumers, UIQ recently launched official Instagram and TikTok accounts. With TikTok serving as a highly influential platform among North American Gen Z audiences, the brand plans to roll out influencer-driven campaigns and viral content to amplify product awareness and engagement. "This Amazon launch marks a significant milestone in UIQ's global expansion and reflects our commitment to integrating advanced biotechnology with high-performance skincare," said a UIQ spokesperson. "With strong product efficacy and a bold marketing strategy, we are aiming to achieve top category rankings during Amazon's Prime Day." UIQ is a skincare brand developed by Genome & Company, Korea's leading microbiome research and development firm. Harnessing proprietary functional microbiome ingredients, UIQ offers tailored product lines including the Barrier line for hydration and skin barrier support, the Remedy line for calming care, and the Vitamin C line for brightening and spot correction, each designed to address specific skin concerns with precision and efficacy. Photo - https://mma.prnasia.com/media2/2687095/Genome___Company_s_Skincare_Brand_UIQ_Expands_North_America_Official.jpg?p=medium600
-
Genome & Company's Skincare Brand UIQ Expands into North America with Official Amazon Brand Store Launch
Official debut signals full-scale entry into global markets Biome Barrier Cream Mist earns 'Amazon's Choice' designation SEOUL, South Korea, May 16, 2025 /PRNewswire/ -- Genome & Company, a global clinical-stage biotechnology firm, has officially launched its skincare brand UIQ (www.theuiq.com) on Amazon, the largest e-commerce platform in the United States. Genome & Company’s Skincare Brand UIQ Expands into North America with Official Amazon Brand Store Launch UIQ, renowned for its patented skin-derived microbiome ingredients targeting a range of skin concerns, aims to solidify its North American presence by leveraging Amazon's expansive platform and enhancing direct engagement with global consumers. Through its dedicated Amazon brand store, UIQ now offers signature products including Biome Barrier Cream Mist (100ml) and Biome Barrier Collagen Firming Cleansing Balm (100ml). These hero products—part of the Biome Barrier, Biome Remedy, and Biome C collections—exemplify the brand's commitment to science-backed, targeted skincare solutions. Notably, the Biome Barrier Cream Mist was awarded the Amazon's Choice badge shortly after launch, in recognition of its superior quality, user reviews, and fulfillment performance. UIQ also reported outstanding performance during its first participation in Amazon's Spring Sale (March 25–31, local time). As of 5:00 PM KST on April 1, sales had surged by approximately 1,900% compared to its average daily revenue—demonstrating significant growth potential in the U.S. market. Customer feedback on Amazon has been overwhelmingly favorable, underscoring the product's efficacy and consumer appeal. Many reviewers praised the mist for being "glow-boosting without feeling heavy" and expressed enthusiasm for "discovering a K-beauty brand genuinely committed to skin science." This successful debut is regarded as a strategic milestone in UIQ's global expansion roadmap. To further strengthen connections with international consumers, UIQ recently launched official Instagram and TikTok accounts. With TikTok serving as a highly influential platform among North American Gen Z audiences, the brand plans to roll out influencer-driven campaigns and viral content to amplify product awareness and engagement. "This Amazon launch marks a significant milestone in UIQ's global expansion and reflects our commitment to integrating advanced biotechnology with high-performance skincare," said a UIQ spokesperson. "With strong product efficacy and a bold marketing strategy, we are aiming to achieve top category rankings during Amazon's Prime Day." UIQ is a skincare brand developed by Genome & Company, Korea's leading microbiome research and development firm. Harnessing proprietary functional microbiome ingredients, UIQ offers tailored product lines including the Barrier line for hydration and skin barrier support, the Remedy line for calming care, and the Vitamin C line for brightening and spot correction, each designed to address specific skin concerns with precision and efficacy.
-
Nuance Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-CHINA Trial for COPD
Statistically significant improvements in lung function Consistent trends of quality of life and exacerbation rate reduction as ENHANCE-1/2 Well tolerated safety profile NDA submission planned for 2H 2025 SHANGHAI, May 16, 2025 /PRNewswire/ -- Nuance Pharma ("Nuance") today announces its top-line Phase 3 ENHANCE-CHINA (NCT05743075) trial results evaluating nebulized ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease ("COPD"). The ENHANCE-CHINA trial has successfully met its primary endpoint, as well as secondary endpoints demonstrating improvements in lung function. The investigational study drug, ensifentrine is a first-in-class selective dual inhibitor of phosphodiesterase 3 and 4 ("PDE3; PDE4") that combines bronchodilator and non-steroidal anti-inflammatory effects in one molecule, delivered directly to the lungs through a standard jet nebulizer without the need for high inspiratory flow rates or complex hand-breath coordination. Highlights - Study population (n = 526 randomized): Subject demographics and disease characteristics were well balanced between treatment groups Approximately 46% of subjects received background COPD therapy, either a long-acting muscarinic antagonist ("LAMA") or a long-acting beta-agonist ("LABA"). Additionally, approximately 38% of all subjects received inhaled corticosteroids ("ICS") with concomitant LABA. - Primary endpoint met (FEV1 AUC 0-12hr): Placebo corrected, change from baseline in average FEV1 area under the curve 0-12 hours post dose at week 12 was 110 mL (p<0.0001) for ensifentrine Statistically significant and clinically meaningful improvements with ensifentrine demonstrated across key subgroups including age, smoking status, COPD severity, background medication, ICS use, chronic bronchitis, FEV1 reversibility - Secondary endpoints of lung function: Placebo corrected, increase in peak FEV1 of 174 mL (p<0.0001) at week 12 Placebo corrected, increase in morning trough FEV1 of 36 ml (p=0.0533) and evening trough FEV1 of 65 ml (p=0.0038) at week 12, confirming twice daily dosing regimen. Placebo corrected, increase in average FEV1 of 162 ml (p<0.0001) 0-4 hours post dose and 77 mL (p=0.0003) 6-12 hours post dose at week 12 - COPD symptoms and quality of life (QoL): Clinically meaningful improvements in dyspnea as measured by Transition Dyspnea Index (TDI) in the ensifentrine group were observed at all weeks (6, 12 and 24) with a statistically significant improvement of 0.8 unit compared to placebo at week 24. Quality of Life (QoL) as measured by St George's Respiratory Questionnaire (SGRQ) Total Score in the ensifentrine group improved from baseline to greater than the MCID of -4 units with a significant improvement of -2.9 units compared to placebo at week 24. Daily symptoms as measured by Evaluating Respiratory Symptoms (E-RS) Total Score in ensifentrine group showed improvement from baseline as early as 6 weeks and continued improvement at 12 and 24 weeks, numerically exceeding placebo at each measurement. - Exacerbation rate reduced Subjects receiving ensifentrine demonstrated a 28% reduction in the rate of moderate/severe COPD exacerbations over 24 weeks compared to those receiving placebo (RR = 0.72, 95% CI: (0.43, 1.22)) Treatment with ensifentrine significantly decreased the risk of a moderate/severe exacerbation as measured by time to first exacerbation when compared with placebo by 25% (HR = 0.75, 95% CI: (0.44, 1.28)) - Favorable safety profile: Ensifentrine was well-tolerated with treatment related AE incidence similar to placebo Mark Lotter, founder and Chief Executive Officer of Nuance Pharma, said:"We are very pleased by the successful outcome of our Phase 3 ENHANCE-CHINA study, bringining us another step closer to providing a much needed novel therapy for COPD patients in China. These promising results demonstrate ensifentrine's strength as a first-in-class bronchodilator and non-steroidal anti-inflammatory therapy for COPD, as an advance to existing treatment options. We plan to submit a New Drug Application to the China NMPA in the second half of 2025. We would like to thank all the patients and investigators for their participation in the ENHANCE-CHINA program. " Charlie Chen, Chief Operating Officer of Nuance Pharma added:"The totality of ENHANCE data including improvements in lung function, symptoms, quality of life measure and reduction in exacerbations, coupled with favorable safety profile, support our belief that ensifentrine will change the treatment paradigm for COPD. Following our ongoing early access programs in Hainan BoAo and Greater Bay Area, as well as regulatory approval in Macau, we look forward to bringing this medicine to patients in Greater China." David Zaccardelli, Pharm. D., President and Chief Executive Officer of Verona Pharma, said:"we look forward to Nuance Pharma's continued progress and having Ohtuvayre® available for the millions of symptomatic patients needing additional treatment." Nuance Pharma plans to release additional information from ENHANCE-CHINA at upcoming scientific conferences. In Feb 2025, the Pharmaceutical Administration Bureau Macau approved Ohtuvayre™ (ensifentrine) for the maintenance treatment of COPD in adult patients. In Nov 2024, Nuance Pharma launched Ohtuvayre™ in China's Hainan Boao Pilot Zone through early access program. In Sep 2024, Nuance Pharma completed recruitment for ENHANCE-CHINA, the phase 3 clinical trial of Ohtuvayre™ (ensifentrine) for the maintenance treatment of COPD. In June 2024, Nuance Pharma's global partner Verona Pharma plc (Nasdaq: VRNA), announced the US Food and Drug Administration ("FDA") approved Ohtuvayre™ (ensifentrine) for the maintenance treatment of COPD in adult patients. In 2021, Nuance Pharma entered into an agreement with Verona Pharma for the exclusive rights to develop and commercialize Ohtuvayre™ (ensifentrine) in Greater China (mainland China, Hong Kong, Macau and Taiwan). About Ohtuvayre ™ (ensifentrine)Ohtuvayre™ is the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Verona has evaluated nebulized Ohtuvayre™ in its Phase 3 clinical program ENHANCE ("Ensifentrine as a Novel inHAled Nebulized COPD thErapy") for COPD maintenance treatment. Ohtuvayre™ met the primary endpoint in both ENHANCE-1 and ENHANCE-2, demonstrating statistically significant and clinically meaningful improvements in lung function. About the ENHANCE-CHINA programThe randomized, double-blind, placebo-controlled study evaluate the efficacy and safety of nebulized ensifentrine as monotherapy and added onto a single bronchodilator, either a LAMA or a LABA, compared to placebo, and subjects may receive ICS. Patient Population: 526 moderate to severe, symptomatic, COPD patients at 46 sites in China. Dose/Duration: subjects were randomized to receive a 3mg nebulized dose of ensifentrine or nebulized placebo twice daily for 24 weeks Primary Endpoint: Improvement in lung function with ensifentrine as measured by average FEV1 AUC 0-12 hours post dose at week 12. Secondary Endpoints: lung function endpoints including peak and morning trough FEV1, COPD symptoms and health related quality of life through 24 weeks via SGRQ and E-RS, and exacerbation at 24 weeks, and others Safety: Assessed over 24 weeks Further information about ENHANCE-CHINA program can be found at www.clinicaltrials.gov (NCT05743075) About Verona PharmaVerona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. Ohtuvayre™ (ensifentrine) is the Company's first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ohtuvayre™ (ensifentrine) has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com. About Nuance PharmaNuance Pharma is an innovation focused biopharmaceutical company, with both late-stage clinical pipeline and commercial stage asset portfolio. Focusing on specialty care, Nuance has established a differentiated combination of commercialized assets and innovative pipeline across respiratory, pain management, emergency care and iron deficiency anemia. With the mission to address critical unmet medical needs in Asia Pacific, Nuance deploys the Dual Wheel model that develops a global leading innovative pipeline, while maintaining a self-sustainable commercial operation in both China and Asia as a region. For more information, please visit www.nuancepharma.com. Forward-looking StatementsThis news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.
-
NWTN Appoints New CEO to Drive Strategic Transformation
DUBAI, UAE, May 16, 2025 /PRNewswire/ -- NWTN Inc. (Nasdaq: NWTN), a Dubai-headquartered Intelligent New Energy Vehicles (NEV) and smart technology company, announced the appointment of Mr. Benjamin Zhai as Executive Director of the Board and Global Chief Executive Officer. This leadership change marks a milestone in NWTN's strategic evolution, transforming from a NEV manufacturer to a global smart technology platform, poised to revolutionize innovation and supply chain ecosystem. The NWTN board announcement stated, "We are excited to have Mr. Zhai to lead the company's transformation and growth in the next phase. Mr. Zhai's deep experience and impressive track record in building and transforming technology companies is a perfect match for our group." Mr. Zhai brings over three decades of global leadership experience across technology, mobility, and venture investment. He has worked extensively in Asia, Americas, Europe and Oceania, and has held senior roles at EDS (now HP), Kearney, Egon Zehnder, and Russell Reynolds, and played critical roles in several high-growth ventures such as NIO. He was former Chairman of NIO Global User Trust, CEO of Canoo (Go EV) China, CEO of Shenzhen Talent Group, Managing Partner of Russell Reynolds' Automotive Practice in Asia Pacific and Americas, Managing Partner of Egon Zehnder's Industrial Practice in Asia Pacific. "NWTN is embarking on an exciting journey, fueled by AI, electrification, and new version of globalization," said Mr. Zhai. "With UAE as our global hub, we are committed to builing a platform combining smart manufacturing, agile supply chains, and industrial-digital finance." Under Mr. Zhai's leadership, NWTN will implement a transformative three-pillar strategy: Global Smart Innovation – Expand product offerings beyond NEVs to include autonomous logistics systems, drones, and smart wearables and other smart devices. Advanced Manufacturing in UAE – Establish the NWTN Smart Industrial Park in Abu Dhabi, integrating R&D, vehicle assembly, and intelligent equipment production to enhance smart manufacturing capabilities. Industrial-Digital Finance Convergence – Leverage the UAE's strengths in industry policy, technology and talent, to create a "technology + manufacturing + capital" model. "There is no better place than UAE to drive NWTN's transformation. We look forward to partnering with technology innovators and entrepreneurs around the world, and we are committed to making this world more intelligent, more connected and more integrated." Mr. Zhai concluded. About NWTN NWTN is a global innovator in smart EVs, green energy solutions, and autonomous driving technologies, headquartered in Dubai, UAE. For Media Enquiries:NWTN PR TeamEmail: pr@nwtn.ae
-
Nordic Bioscience launches novel Endotrophin assay
HERLEV, Denmark, May 16, 2025 /PRNewswire/ -- Nordic Bioscience introduces nordicEndotrophin™, a fully automated high-precision assay that selectively quantifies the intact 77-amino-acid Endotrophin signaling hormone—qualified in the CAP/CLIA certified Nordic Bioscience laboratory. When integrated with the company's existing product line, the biomarker assay demonstrated prognostic utility in fibrosis and cancer studies1. NordicEndotrophin™ joins nordicPRO-C6™ and nordicPRO-C3™ (in-house versions of the FDA-supported PRO-C6 and CE approved PRO-C3 assays) to deliver a one-stop solution for assessing the fibro-inflammatory axis in chronic diseases, including cardiovascular, metabolic, renal and more. Following PRO-C3's recent deployment on Roche IVD platforms, the new Endotrophin assay strengthens risk stratification and pharmacodynamic monitoring. Endotrophin was first identified in 2012 as a collagen-derived hormone released from type VI collagen. Type VI collagen is a contributor to fibroblast activation and driver of fibrosis across organs—inflammatory processes that underlie roughly 40 percent of deaths in Western countries2. Obesity exacerbates this by activating fibroblasts in the liver, kidney and heart. Across a range of chronic diseases, patients with a two-fold increase of circulating Endotrophin levels increased risk of mortality by 100%1,2. Quantifying Endotrophin enables researchers to connect wound healing and fibrotic progression to patient outcomes, supporting precision-medicine approaches that pharmacodynamically modulate this dangerous hormone. Whereas PRO-C6, Nordic Bioscience's first hand-held ELISA assay measuring the formation of the total pool of type VI collagen (a3 chain encompassing 12 Von Willebrand binding domains), a collagen responsible for binding of platelets that cause fibroblast activation and would healing, nordicEndotrophin™ specifically measures the intact 77-amino-acid hormone. This specificity means additional risk stratification and prognostic value that complement PRO-C6's fibrosis-driven pharmacodynamic insights1. "Endotrophin is a significant prognostic biomarker to emerge," said CEO Dr. Morten Karsdal. "Evidenced in a study of HFpEF patients, Endotrophin and PRO-C6 outperformed NT-proBNP in HFpEF for mortality and hospitalization risk3. Together with PRO-C3, quantifying this fibro-inflammatory hormone will refine patient stratification and treatment monitoring across obesity, fibrotic diseases, and autoimmune endotypes." Offered in Nordic Bioscience's CAP/CLIA-certified laboratory in Herlev, Denmark, the nordicEndotrophin™ high-precision sandwich assay is available on fully automated, high-accuracy, high-throughput platforms. To accelerate drug fibro-inflammatory profiling, clients considering nordicEndotrophin™ are invited to co-measure nordicPRO-C3™ and nordicPRO-C6™. Together, these assays facilitate precise risk stratification, dose selection, patient enrichment, proof-of-mechanism and treatment monitoring in anti-fibrotic and oncology trials2. About Nordic Bioscience Nordic Bioscience is a Danish biomarker company headquartered in Herlev, Denmark. We are engaged in biomarker development using our unique neoepitope technology. We combine our expertise in biomarker development with preclinical and clinical research. This enables us to develop biomarkers that provide fast and objective decision-making for compound selection and development in clinical trials as well as provide value for patients in a diagnostic setting. For more information about Nordic Bioscience, visit us at https://www.nordicbioscience.com References: [1] https://pubmed.ncbi.nlm.nih.gov/38871093/ [2] https://pubmed.ncbi.nlm.nih.gov/38091968/ [3] https://pubmed.ncbi.nlm.nih.gov/37645406/ For product related inquires please use https://www.nordicbioscience.com/contact
-
Amorepacific and Johns Hopkins School of Medicine's Joint Research Program 'NBRI' Participants Present Latest Findings
Skin anti-aging and immunity effects of Amorepacific's two proprietary ingredients, 'RE.D Flavonoid' and 'Senomune' revealed at the 2025 SID Annual Meeting SEOUL, South Korea, May 16, 2025 /PRNewswire/ -- Amorepacific has demonstrated the efficacy of its two proprietary ingredients in improving skin aging and immune response through the NBRI program, jointly operated with Johns Hopkins School of Medicine. The findings were presented at the 2025 SID (Society for Investigative Dermatology) Annual Meeting in San Diego, California, last week. NBRI (New Beauty Research Initiative) is a collaborative research program that Amorepacific has maintained with the Department of Dermatology at Johns Hopkins School of Medicine since 2022. The two organizations conduct multifaceted research cooperation on skin aging. At this year's SID meeting, NBRI program participants Professor Anna Chien's research team presented the efficacy of Amorepacific's bio-flavonoid ingredient, RE.D Flavonoid, and Professor Martin Alphonse's research team presented the benefits of the green tea-derived ingredient, Senomune. Professor Anna Chien's team confirmed that RE.D Flavonoid, derived from the camellia plant, effectively improves photo-aging symptoms on the face and neck area without irritation. Notable improvements were observed across significant signs of skin aging, including fine lines, skin texture, pores, radiance, and pigmentation, with substantial changes in skin texture and radiance appearing from the eighth week of use. This research was based on long-term results from North American consumers of diverse ethnicities who used RE.D Flavonoid for six months. The study indicates that RE.D Flavonoid works by blocking signal transmission in skin aging and inhibiting collagen damage, which is crucial for skin elasticity. Professor Martin Alphonse's team revealed that Senomune, a saponin component from green tea extract, mitigates immune cell damage and inflammatory responses caused by particulate matter (PM). The team also confirmed the potential for Senomune to reduce immune aging and chronic inflammatory reactions due to external environmental factors by balancing the metabolic functions of immune cells. This research was conducted using peripheral blood mononuclear cells (PBMC) from humans, and researchers observed reduced stress responses in immune cells to environmental harmful elements in groups pre-treated with the ingredient. Dr. Suh Byung-fhy, CTO and Head of Amorepacific's R&I Center, stated, "The ongoing NBRI collaborative research program for Skin Longevity of our global customers provides a valuable opportunity to demonstrate the scientific excellence of Amorepacific's slow-aging skincare technology," adding, "Amorepacific will continue to focus on beauty solution research aimed at activating the skin's fundamental recovery capabilities beyond mere symptom improvement." The Society for Investigative Dermatology (SID) is an organization dedicated to advancing the sciences relevant to skin disease and has held annual meetings since its establishment in 1937. At this year's 82nd conference, more than 1,600 researchers, clinicians, and dermatology residents from around the world gathered to present over 1,200 of the latest skin research findings. Results from RE.D Flavonoid application test, presented at the 2025 SID Annual Meeting, showing notable improvements across significant signs of skin aging, including fine lines, skin texture, pores, radiance, and pigmentation, with substantial changes in skin texture and radiance Visual representation of test results, presented at the 2025 SID Annual Meeting, showing Senomune, a saponin component from green tea extract, counteracting the effects of particulate matter (PM)
-
CeMAT Southeast Asia - The Leading Intralogistics & Supply Chain Fair Opens in 3 days
SINGAPORE, May 16, 2025 /PRNewswire/ -- CeMAT Southeast Asia, the leading logistics and supply chain innovation trade event, is set to open in days, running 19 to 21 May 2025 at Singapore EXPO. Bringing together leading technology and service providers, CeMAT Southeast Asia will offer a one-stop hub for the latest in intralogistics, robotics and automation, warehousing, supply chain management, and materials handling. Attendees at this year's event can expect cutting-edge product demonstrations, industry-leading solutions, and deep dives into best practice across key sectors, including e-commerce, manufacturing, food industry, pharmaceutical, FMCG, supply chain management and retail. With 65+ exhibitors, attendees can network with key industry leaders. Notable top exhibitors include SSI Schaefer, Dematic, Honeywell, Körber Supply Chain, KARDEX, Geek+, AutoStore, Swisslog, Samsung SDS Asia Pacific, Hyster-Yale Asia Pacific and many more. Mike Nissen, Commercial Director, Hannover Fairs Asia Pacific commented on the challenges and innovations driving the sector. "Southeast Asia's logistics sector is evolving fast. With companies building more resilient supply chains, digitalization, skills development, and sustainability are becoming priorities." "At the same time, growth in e-commerce, regional trade deals like RCEP, and automation are reshaping the industry. With its strategic location and tech momentum, Southeast Asia is set to lead in supply chain innovation. CeMAT Southeast Asia 2025 is proud to drive this transformation forward." A highlight is the Singapore Hour — where exhibitors from the Singapore Pavilion talk about cutting-edge innovations in automation, warehousing, supply chain technology, and logistics. Additionally, the Knowledge Theatre, sponsored by SSI SCHAEFER, will feature expert-led sessions, offering insights and solutions for professionals in logistics and warehousing, with sessions on Industry leaders such as Carsten Spiegelberg, Head of Logistics Solutions APAC & MEA at SSI Schaefer, Alex Ch'ng, Business Development Manager at AutoStore, and Terrence Chan, Senior Sales Manager at Dematic, will share their expertise and insights on: The AI Revolution – How artificial intelligence is transforming logistics and supply chain operations. Future-Ready Intralogistics – Innovations shaping warehouse efficiency and supply chain agility. Robotics Excellence – The latest advancements in warehouse robotics and automation. Scalable SME Automation – Smart automation solutions tailored for small and medium-sized enterprises. Hot Trends in Cold Chain – Evolving best practices in temperature-controlled logistics. Sustainable and Secure Supply Chains – Strategies for building resilient, eco-friendly supply networks. The Warehouse of the Future – Technologies shaping next-generation warehousing and fulfilment. CeMAT Southeast Asia 2025 will once again host the LogiSYM Asia Pacific conference on May 20–21 at the Singapore EXPO. This premier event brings together logistics and supply chain leaders to share practical insights, explore innovations, and tackle industry challenges. With thought-provoking discussions and interactive sessions, the partnership between CeMAT and LogiSYM offers aligned opportunities for networking, collaboration, and industry advancement. For more information and to register, visit https://cematseasia.com/. About Hannover Fairs Asia Pacific Hannover Fairs Asia Pacific is part of Deutsche Messe AG . Deutsche Messe was founded in 1947 with the Hannover Export Fair but has grown to become a globally significant events business operating events and venues around the world. The business operates 9 subsidiary offices including in the US and China, hosts events in over 48 locations, with sales activities in 110 countries. The company is owned by the State of Lower Saxony and the City of Hannover. Our team has a wealth of experience in running events of all shapes and sizes in a vast range of geographies. Their passion is in creating great events that make a difference to the industry's they serve. Welcome to Hannover Fairs Asia Pacific, we look forward to seeing you at one of our events soon.
-
PHKL Showcases Robotic Precision in Orthopaedic Care
KUALA LUMPUR, Malaysia, May 16, 2025 /PRNewswire/ -- Pantai Hospital Kuala Lumpur (PHKL) recently hosted its first-ever Ortho Experience Day, offering a rare, hands-on look at the hospital's cutting-edge MAKO Robotic Surgery System—a transformative tool in joint replacement procedures. Dr Rizal Abdul Rani, Orthopaedic Surgery Specialist, demonstrating with the Mako Surgical System Guests were invited to operate the robotic arm on a surgical dummy, experiencing first-hand how robotic-assisted technology improves surgical precision, implant placement, and recovery time. PHKL's orthopaedic specialists were also on hand to discuss the evolving landscape of bone, joint, and sports injury treatments. Robotic-assisted joint replacement surgery offers a range of benefits for patients, including: Greater surgical precision and implant accuracy Personalised surgical planning based on each patient's anatomy Reduced soft tissue damage and post-operative pain Faster recovery times and shorter hospital stays Improved long-term joint function and implant lifespan The hands-on experience reflects PHKL's long-term commitment to integrating state-of-the-art technologies not only in patient care, but also in the training and upskilling of medical professionals, ensuring patients receive the most advanced and personalised treatments available. With joint conditions such as osteoarthritis affecting more Malaysians each year, PHKL is proud to highlight its ongoing commitment to advanced technologies that support faster recovery, improved outcomes, and personalised orthopaedic care. For more information on Pantai Hospital Kuala Lumpur's services in Robotic Surgery, visit www.pantai.com.my/kuala-lumpur/robotics. About Pantai Hospital Kuala Lumpur For five decades, Pantai Hospital Kuala Lumpur has been the heartbeat of Kuala Lumpur, steadfastly delivering exceptional care to patients from all walks of life. Since its inception in 1974 with just 68 beds and 20 medical specialists, the hospital has grown into a healthcare icon today with 507 beds, over 200 consultants and counting. Our pursuit of quality healthcare, clinical excellence, and cutting-edge technology is underscored by our service quality and dedication towards clinical research. This has earned us accreditations from the Malaysian Society for Quality in Health (MSQH) and the Joint Commission International (JCI). Additionally, we hold certification as a Baby-Friendly Hospital and is a preferred hospital in Malaysia by the World Health Organization (WHO). As we celebrate our 50th anniversary, Pantai Hospital Kuala Lumpur looks to the future, unwaveringly committed to continuing its legacy of excellence with world-class healthcare services and innovative treatments for generations to come. Learn more at www.pantai.com.my/kuala-lumpur. For more information, please contact: Callie Phin, Pantai Hospital Kuala Lumpur Email: callie.phin@pantai.com.my Tel No.: 014-686 7066